Previous studies revealed that as a B-lymphoid transcription factor, PAX5 was downregulated in over 80% of pre-B cell acute lymphoblastic leukaemia (ALL), and its downregulation in lymphoid neoplasms was associated with promoter hypermethylation and poor clinical outcomes [37, 38]. The gene discussed is PAX5; the disease is lymphoid neoplasm.